Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer

Affiliations

Comment

Akiko Ota et al. J Clin Oncol. 2017.

. 2017 Feb 20;35(6):691-692.

doi: 10.1200/JCO.2016.70.4148. Epub 2016 Dec 5.

¹ Akiko Ota, Bishal Gyawali, Ayumu Matsuoka, and Yuichi Ando, Nagoya University Hospital, Nagoya, Japan.

No abstract available

Comment in

Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al.
Yang JC, Puri T, Orlando M, Cheng Y. Yang JC, et al. J Clin Oncol. 2017 Feb 20;35(6):694-695. doi: 10.1200/JCO.2016.70.6978. Epub 2016 Dec 5. J Clin Oncol. 2017. PMID: 27918723 No abstract available.

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Cheng Y, et al. J Clin Oncol. 2016 Sep 20;34(27):3258-66. doi: 10.1200/JCO.2016.66.9218. Epub 2016 Aug 9. J Clin Oncol. 2016. PMID: 27507876 Clinical Trial.